Incyte Corporation
INCYNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $24.35B
- P/E (TTM)
- 15.10
- Forward P/E
- 8.04
- Dividend yield
- -
- 52-week range
- $84.02$132.60
- Volume (live)
- -
- Avg. volume (3M)
- 1.72M
Incyte (INCY) Stock Price & Financial Analysis
Incyte Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $112.76 - $117.17 |
|---|---|
| 52-Week High | $132.60 |
| 52-Week Low | $84.02 |
| Open | $113.93 |
| Volume (last close) | 2.24M |
| Average Volume (3M) | 1.72M |
| Revenue (TTM) | 5.82B |
|---|---|
| Net Income (TTM) | 1.61B |
| Free Cash Flow (TTM) | 1.89B |
| EPS (TTM) | $7.85 |
| Profit Margin | 27.71% |
| Operating Margin | 31.57% |
| Return on Equity (ROE) | 25.41% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 24.35B |
|---|---|
| Shares Outstanding | 208.22M |
| P/E Ratio (TTM) | 15.10 |
| Forward P/E | 8.04 |
| Price to Sales (P/S) | 4.18 |
| Price to Book (P/B) | 3.84 |
| EV/EBITDA | 10.11 |
| 50-Day MA | $121.59 |
|---|---|
| 200-Day MA | $107.65 |
| 1-Year Change | +30.93% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Incyte at a Glance
As of the Oct 22, 2026 close, Incyte (INCY) has a market capitalization of $24.35B. The stock trades at 15.1× trailing earnings, 8.0× forward earnings and 4.2× sales. Over the trailing twelve months it earned $1.61B on revenue of $5.82B (a 27.7% profit margin) and generated $1.89B of free cash flow. Revenue grew 26.9% year over year.
As of its latest reported balance sheet, it holds $3.98B in cash and securities against $38.27M of debt, a net cash position of $3.94B.
Incyte does not currently pay a dividend.
The share price is up 30.9% over the past year. At $116.93 (the Oct 22, 2026 close) it sits within its 52-week range of $84.02 to $132.60, above its 200-day moving average of $107.65.
Based on 22 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $131.70, 12.6% above the Oct 22, 2026 close.
Frequently Asked Questions About Incyte
What is the current stock price for INCY?
As of the Oct 22, 2026 close, INCY stock trades at $116.93. The 52-week range is $84.02–$132.60, with a day range of $112.76–$117.17.
What is the P/E ratio for INCY?
As of the Oct 22, 2026 close, Incyte's trailing twelve-month (TTM) P/E ratio is 15.1, meaning investors pay $15.1 for every $1 of annual earnings. The forward P/E is 8.0, reflecting analyst expectations for future earnings. Incyte operates in the Healthcare sector.
Does INCY pay dividends?
Incyte does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for INCY?
Based on ratings from 22 professional analysts over the last 90 days, the consensus for INCY is Buy. The average 12-month price target is $131.70, a 12.6% upside from the Oct 22, 2026 close of $116.93.
What is the market cap of INCY?
As of the Oct 22, 2026 close, Incyte's market capitalization is $24.35B, classifying it as a large-cap company. Incyte operates in the Healthcare sector within the Biotechnology industry.